India has affirmed the primary rundown of 13 nations that are set to get COVID-battling drugs from India, including the anti-malaria drug, hydroxychloroquine, or HCQ.
The first list includes 13 countries -- US, Spain, Germany, Bahrain, Brazil, Nepal, Bhutan, Afghanistan, Maldives, Bangladesh, Seychelles, Mauritius, and the Dominican Republic.
Addressing media on Friday, Joint Secretary in the Ministry of External Affairs, Dammu Ravi, stated, "A lot of requests for HCQ were already there and taking into view domestic stock and requirement while keeping a sufficient buffer, a decision was taken by the Group of Ministers to release some of the surplus medicine for export purposes."
Dammu Ravi informed that there will be two more such consignments of the coveted drug that will be exported to foreign nations.
In the midst of anxieties whether India had adequate hydroxychloroquine stock itself, the wellbeing service educated that in the coming week, India will require 1 crore tablets for household use and current stock stands at over 3.28 crore.
The United States had requested 48 lakh tablets of hydroxychloroquine. India, in the meantime, has authorized 35.82 lakhs tablets alongside India 9 metric ton (MT) API (dynamic pharmaceutical fixing), according to their solicitation.
Other than the USA, just Brazil, Canada, and Germany are relied upon to get 50 lakh tablets every one of hydroxychloroquine in the subsequent transfer.
In the principal transfer, Brazil will get 0.53 MT of API and Germany, 1.5 MT of API. Bangladesh is set to get 20 lakh tablets of hydroxychloroquine, Nepal 10 lakh, Bhutan 2 lakh, Sri Lanka 10 lakh (not in the principal transfer), Afghanistan 5 lakh, and Maldives 2 lakh.
The MEA said that the countries were shortlisted on a first come first serve basis. India will also be exporting a total of 430 million tablets of paracetamol.